Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Perception That Antibiotics Are Harmless is Widespread

By Center for Disease Dynamics, Economics & Policy | June 1, 2018

A new study of decision-making about the use of antibiotics in medicine has found that the mistaken belief that antibiotics are harmless is widespread, especially among patients. Clinicians and patients alike are influenced by the general notion of “why not take a risk” (“WNTAR”), a belief that there is potential benefit and very little risk in taking antibiotics, when in reality there are specific downsides, both for individuals and for society as a whole.

The team of researchers from George Washington University, Center for Disease Dynamics, Economics & Policy (CDDEP), University of California-Davis, Cornell University, and Johns Hopkins University surveyed 149 clinicians and 225 patients from two large urban academic hospitals and 519 online non-patient subjects to determine whether providers share patients’ rationales for antibiotic use. They discovered that when comparing the status quo of remaining sick to the potential benefits of antibiotic use, patients are more likely to expect antibiotics, leading clinicians to prescribe them more despite having a greater knowledge of the drugs and their side effects. The research was published May 30, 2018 in the journal Medical Decision Making.

The study–Patients’ and Clinicians’ Perceptions of Antibiotic Prescribing for Upper Respiratory Infections in the Acute Care Setting–also found the “WNTAR” belief can lead to increased healthcare costs and adverse reactions, such as antibiotic resistance and secondary infections.

“The problem is that patients, but more surprisingly clinicians, are not fully recognizing the potential harms from antibiotic use”, said Dr. Klein of CDDEP. “Despite the fact that approximately 20% of patients can get some sort of side effect, this does not seem to be as important a factor in decision-making as one would expect.”

Dr. Broniatowski and colleagues hope a better understanding of this issue will lead to the development of educational strategies that can be used to communicate risks and consequences, with the ultimate goal of reducing inappropriate prescribing and alleviating antibiotic resistance.

“The most important driver of antibiotic resistance is antibiotic use,” Dr. Klein added. “Eliminating unnecessary antibiotic use would eliminate unnecessary harms to patients, and help reduce the spread of antibiotic resistance, which threatens the medical gains of the last century.”


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE